• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Mycoplasma synoviae vaccine modifies virus shedding and immune responses of avian influenza (H9N2) infection in commercial layers

tetano

Editor, Senior Moderator
Poult Sci. 2017 Sep 1;96(9):3086-3095. doi: 10.3382/ps/pex149.
[h=1]Mycoplasma synoviae vaccine modifies virus shedding and immune responses of avian influenza (H9N2) infection in commercial layers.[/h] Umar S[SUP]1[/SUP], Tanweer M[SUP]2[/SUP], Iqbal M[SUP]3[/SUP], Shahzad A[SUP]4[/SUP], Hassan F[SUP]2[/SUP], Usman M[SUP]2[/SUP], Sarwar F[SUP]2[/SUP], Qadir H[SUP]5[/SUP], Asif S[SUP]6[/SUP], Un-Nisa Q[SUP]4[/SUP], Younus M[SUP]7[/SUP], Ali A[SUP]5[/SUP], Akbar M[SUP]2[/SUP], Towakal F[SUP]2[/SUP], Shah MA[SUP]1[/SUP].
[h=3]Author information[/h]

[h=3]Abstract[/h] Mycoplasma synoviae (MS) is an important pathogen of domestic poultry and is prevalent in commercial layers. Avian influenza (AI; H9N2) infections are emerging respiratory problems causing huge economic losses to the poultry industry, especially in the presence of other co-infecting pathogens. The possible role of MS vaccination and response to AI (H9N2) virus in commercial layers was evaluated during this study. Experimental commercial layers were divided into different groups which were identified as follows: non-vaccinated non-challenged (NVNC), non-vaccinated challenged (NVC), vaccinated non-challenged (VNC), and vaccinated challenged (VC). The titer of AI antibodies was measured pre- and post-challenge to confirm experimental infection. Infected layers showed clinical signs of differing severity, with the most prominent disease signs and mortality (25%) appearing in layers of the VC group. Moreover, the layers in VC group showed a significant decrease in weight and enhanced gross lesions. All infected layers showed positive results for virus shedding; however, the pattern of virus shedding was different, with layers of VC group showing more pronounced virus excretion than the layers in the NVC group. In addition, layers of VC group showed significantly reduced antibody responses and interferon gene expression when compared with the layers of NVC group. The present study revealed that MS vaccine could facilitate replication of avian influenza viruses and thus avian influenza virus infections can be worse after MS vaccination, especially in AIV-endemic areas.
Published by Oxford University Press on behalf of Poultry Science Association 2017.


[h=4]KEYWORDS:[/h] Mycoplasma synoviae; avian influenza; immunity; layer; replication; vaccine

PMID: 28854756 DOI: 10.3382/ps/pex149
 
Back
Top Bottom